A share price of BioAtla Inc [BCAB] is currently trading at $0.8, down -3.05%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BCAB shares have gain 15.57% over the last week, with a monthly amount glided 30.07%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BioAtla Inc [NASDAQ: BCAB] stock has seen the most recent analyst activity on August 13, 2025, when Citizens JMP downgraded its rating to a Mkt Perform. Previously, H.C. Wainwright downgraded its rating to Neutral on November 13, 2024. On September 15, 2022, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $17 on the stock. Credit Suisse downgraded its rating to a Neutral and decreased its price target to $5 on May 05, 2022. H.C. Wainwright initiated its recommendation with a Buy and recommended $25 as its price target on March 21, 2022. In a note dated June 28, 2021, ROTH Capital initiated an Buy rating and provided a target price of $75 on this stock.
BioAtla Inc experienced fluctuations in its stock price throughout the past year between $0.24 and $2.53. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. BioAtla Inc [NASDAQ: BCAB] shares were valued at $0.8 at the most recent close of the market. An investor can expect a potential return of 525.0% based on the average BCAB price forecast.
Analyzing the BCAB fundamentals
Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -5.8%, Pretax Profit Margin comes in at -5.41%, and Net Profit Margin reading is -5.41%. To continue investigating profitability, this company’s Return on Assets is posted at -2.19, Equity is -11.32 and Total Capital is -6.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7367 points at the first support level, and at 0.6784 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8666, and for the 2nd resistance point, it is at 0.9382.
Ratios To Look Out For
To put it in perspective, the Current Ratio for BioAtla Inc [NASDAQ:BCAB] is 1.24. As well, the Quick Ratio is 1.24, while the Cash Ratio is 1.1. Considering the valuation of this stock, the price to sales ratio is 4.24.
